期刊文献+

微小RNA-21在弥漫大B细胞淋巴瘤中的表达及其临床意义 被引量:6

Significance of micro RNA-21 expression in diffuse large B-cell lymphoma
原文传递
导出
摘要 目的研究微小RNA-21(miR-21)在弥漫大B细胞淋巴瘤(DLBCL)中的表达,探讨miR-21表达与DLBCL发生、发展的意义及其与临床病理特征和预后的关系。方法采用实时荧光定量聚合酶链反应(RT—PCR)检测50例DLBCL存档蜡块和12例正常淋巴结中miR-21的表达,并采用免疫组织化学EnVision法检测bcl-2、p53在DLBCL中的表达。结果miR-21在DLBCL中高表达,且在非生发中心B细胞样(non—GCB)亚型中高于GCB亚型,50例DLBCL中有18例(36.0%)表达bcl-2,21例(42.0%)表达p53。DLBCL中miR-21表达水平与bcl-2呈负相关(P=0.020),与p53表达、DLBCL临床分期呈正相关(P=0.022;P=0.005),miR-21高表达的DLBCL患者3年生存率较miR-21低表达者低。结论miR-21高表达可能是DLBCL恶性度高的标志,是促进DLBCL肿瘤细胞增殖的重要因素,可能对预后有一定的指导意义。bcl-2、p53可能是miR-21在DLBcL中发挥作用的靶标。 Objective To investigate the expression of miR-21 in diffuse large B cell lymphoma (DLBCL) and normal lymph tissues and its potential relevance with clinicopathological characteristics. Methods The expression levels of miR-21 in 50 primary DLBCL and 12 normal lymph node tissue specimens were examined by TaqMan real-time polymerase chain reaction.The expression of bcl-2 and p53 was detected by immunohistochemistry staining. Results The expression of miR-21 was significantly higher in tumor tissues than that in normal tissues, in GCB subtypes higher than in non-GCB subtypes. And it was negatively correlated with bcl-2 (P=O.020), while positively correlated with p53 (P=0.022). Up-regulated miR-21 expression was low in three years of survival rate. Conclusion MiR-21 may indicate a more aggressive phenotype and serve as a molecular prognostic marker in DLBCL. High-expression of miR-21 is a key feature that is correlated with cell proliferation in DLBCL. miR-21 may have some guiding significance in prognosis, bcl-2, p53 is possibly one of the targets of miR-21 in DLBCL.
出处 《白血病.淋巴瘤》 CAS 2012年第5期269-272,共4页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 大细胞 弥漫性 微RNA21 实时聚合酶链反应 Lymphoma, large cell, diffuse Micro RNA 21 Real-time polymerase chain reaction
  • 相关文献

参考文献12

  • 1马旭东,吴文乔,沈洪武,郑瑞玑.非霍奇金淋巴瘤EB病毒与p53,bcl-2,C-myc蛋白表达及其意义[J].白血病.淋巴瘤,2003,12(5):278-281. 被引量:6
  • 2Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans. 2009, 37:918-925.
  • 3白世平,罗绪刚,吕林.线粒体在细胞凋亡中的介导作用[J].生命科学,2006,18(4):368-372. 被引量:7
  • 4Shi L, Chen J, Yang J, et al. MiR-21 protected human glioblastoma U87MG ceils from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res, 2010, 1352: 255-264.
  • 5Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B cell-like and actirated B cell- like subtypes of diffuse large B cell lymphoma. Int J Cancer, 2007, 121: 1156-1161.
  • 6王艳君,孟丹.bcl-2与NF—κB/p65在弥漫性大B细胞淋巴瘤不同亚型中表达的意义[J].白血病.淋巴瘤,2009,18(10):592-595. 被引量:6
  • 7Chan SH, Wu CW, Li AF, et al. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res, 2008, 25: 907-911.
  • 8Chan JA, Krichevsky AM, Kosik KS, et al. MicroRNA-21 is an antiapoptotie factor in human glioblastoma cells. Cancer Res, 2005, 65: 6029-6033.
  • 9Robertus JL, Harms G, Blokzijl T, et al, Specific expression of miR- 17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol, 2009,22: 547-555.
  • 10Jovanovic MP, Jakovic L, Bogdanovic A, et al. Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and ki-67-positive tumor cells. Vojnosanit Pregl, 2009, 66: 738-743.

二级参考文献68

  • 1Hockenbery D, Nunez G, Milliman C, et al:Bel-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 1990, 348: 334-336.
  • 2Barrans SL, Evans PA, O' Connor SJ, et al. The t (14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res,2003, 9: 2133-2139.
  • 3Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue mieroarray. Blood, 2004, 103: 275-282.
  • 4PDePaepe, C De Wolf-Peeters. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia, 2007, 21: 37-43.
  • 5Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403:503-511.
  • 6Bea S, Zettle A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood, 2005, 106: 3183-3190.
  • 7Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol, 2004, 165: 159-166.
  • 8Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kB activity is required for survival of activated B cell-like diffuse large B-cell lymphoma cells. J Exp Med, 2001, 194: 1861- 1874.
  • 9Tosato G.Tata K,Angiolillo A L,et al, Epstein-Barr virus asan agent of hematological disease[J]. Balliere's Clln Hematol,1995.8( 1 ) : 165- 199.
  • 10Scoll N,Sagar P,Stewart J.et al. p53 in colorectal cacer clinicopathological correlation and prognosis siglnificance[J]. Br JCancer. 1991,63(2) :317- 319.

共引文献16

同被引文献45

  • 1Lee RC, Feinbaum RL, Ambros V, et al. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75: 843-854.
  • 2Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature, 2000, 403: 901-906.
  • 3Lee Y, Ahn C, Han J, et al. The nuclear RNase Ⅲ Drosha initiates miRNA processing. Nature, 2003, 425: 415-419.
  • 4Schwarz DS, Hutv6gner G, Du T, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell, 2003, 115: 199-208.
  • 5Fang C, Zhu DX. Serum miRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol, 2012, 91: 553-559.
  • 6Alencar A J, Malumbres R. MiRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R- CHOP. Clin Cancer Res, 2011, 17: 4125-4135.
  • 7Zhong H, Xu L, Zhong JH, et al. Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin- embedded tissue of patients with diffuse l~rge B-cell lymphoma. Exp Thor Med, 2012, 3: 763-770.
  • 8Rai D, Kim SW. Targeting of SMAD5 links miRNA-155 to the TGF- beta pathway and lymphomagenesis. Proc Natl Acad Sci U S A, 2010, 107:3111-3116.
  • 9Dagan LN, Jiang X. MiR-155 regulates HGAL expression and increases lymphoma cell motility. Blood, 2012, 119:513-520.
  • 10Huang X, Shen Y. Quantitative proteomics reveals miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. Am J Pathol, 2012, 118: 26-33.

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部